Tacrolimus: issues of practical use in atopic dermatitis – analysis of the positional consensus statement of the group of european experts
Atopic dermatitis (AD) is one of the most common chronic inflammatory skin diseases. Treatment goals include induction of remission (control of active disease) and maintenance of remission (prevention of subsequent exacerbations). Topical drugs are the main component of AD therapy and include, first of all, topical glucocorticosteroids (TGCS) and topical calcineurin inhibitors (TICs). TECs have a mechanism of action that is fundamentally different from that of TGCS – they are selective T-cell suppressors that suppress the activation of T-lymphocytes and their production of a wide range of proinflammatory cytokines. Over the years of practical use of the TEC class, a huge array of data has been accumulated from the standpoint of evidence-based medicine – the results of dozens of randomized double-blind studies, summarized in a number of meta-analyses, provide the highest level of evidence for their use in the treatment of AD. In 2018, an article was published in the journal of the European Academy of Dermatology and Venereology – a positional consensus statement of a group of European experts. Understanding the practical value of this work, which answers most of the questions on the practice of using TECs, we decided to highlight and discuss its provisions within the framework of this publication. The main provisions of this article on the use of tacrolimus and pimecrolimus in AD were analyzed, taking into account the consensus and the authors’ own experience.Kruglova L.S., Bakulev A.L., Petrunin D.D., Uspenskaya P.A.
Keywords
atopic dermatitis
topical calcineurin inhibitors
tacrolimus
pimecrolimus
topical glucocorticosteroids
About the Authors
Corresponding author: Dmitry D. Petrunin, Cand. Sci. (Med.), dermatovenerologist, immunologist-allergist, medical director of LEO Pharmaceutical Products LLC, Moscow, Russia; prof.preobrazhenskii@gmail.comSimilar Articles
